Department of Neurology, National Cerebral and Cardiovascular Center, 6-1, Kishibe-shimmachi, Suita 564-8565, Japan.
Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Nutrients. 2024 Oct 4;16(19):3377. doi: 10.3390/nu16193377.
: Equol has protective effects against coronary artery disease and dementia by strongly binding to estrogen receptor beta, whereas the intake of soy isoflavone alone does not always confer such protective effects. Equol production is completely dependent on the existence of equol-producing gut microbiota. The effects of equol-producing status on the cerebrovascular diseases remain unclear. The current study was aimed to investigate the association of equol-producing status with the development of stroke and its neurological prognosis. : Frequencies of equol producers were compared between healthy subjects (HS) registered in the Suita Study and patients with acute stroke admitted to our stroke center from September 2019 to October 2021 in a retrospective cohort study. : The proportion of HSs and patients with ischemic stroke who were equol producers did not significantly differ (50/103 [48.5%] vs. 60/140 [42.9%], = 0.38). However, cardioembolic stroke was significantly associated with low a prevalence of equol producers (adjusted odds ratio [aOR] 0.46, 95% confidence interval [CI] 0.21-0.99, = 0.05). A higher left atrial volume index was observed in equol nonproducers (46.3 ± 23.8 vs. 36.0 ± 11.6 mL/m, = 0.06). The equol nonproducers had a significantly higher prevalence of atrial fibrillation than the equol producers (27.5% vs. 13.3%, = 0.04). Furthermore, the equol producers exhibited a significantly favorable functional outcome upon discharge (aOR 2.84, 95% CI 1.20-6.75, = 0.02). : Equol is a promising candidate for interventions aiming to reduce the risk of CES and atrial dysfunction, such as atrial fibrillation and improve neurological prognosis after ischemic stroke.
大豆苷元通过与雌激素受体β紧密结合，对冠状动脉疾病和痴呆具有保护作用，而单独摄入大豆异黄酮并不总是具有这种保护作用。大豆苷元的产生完全依赖于产生大豆苷元的肠道微生物群的存在。产生大豆苷元的状态对脑血管疾病的影响尚不清楚。本研究旨在探讨产生大豆苷元的状态与中风的发展及其神经预后的关系。
在一项回顾性队列研究中，比较了 2019 年 9 月至 2021 年 10 月期间在大阪府吹田市注册的健康受试者（HS）和因急性中风入住我们中风中心的患者中产生大豆苷元的状态的频率。
HS 组和缺血性中风患者中产生大豆苷元的比例无显著差异（50/103 [48.5%] vs. 60/140 [42.9%]， = 0.38）。然而，心源性脑栓塞与大豆苷元产生者比例低显著相关（调整后的优势比[aOR]0.46，95%置信区间[CI]0.21-0.99， = 0.05）。在非大豆苷元产生者中观察到更高的左心房容积指数（46.3 ± 23.8 与 36.0 ± 11.6 mL/m， = 0.06）。非大豆苷元产生者心房颤动的患病率显著高于大豆苷元产生者（27.5%与 13.3%， = 0.04）。此外，大豆苷元产生者在出院时的功能预后明显较好（调整后的优势比[aOR]2.84，95%置信区间[CI]1.20-6.75， = 0.02）。
大豆苷元是一种有前途的候选物，可用于干预旨在降低 CES 和心房功能障碍（如心房颤动）风险，并改善缺血性中风后的神经预后。
